Institutional interest in medical device makers is holding up—and, in some corners, building—on the back of solid operating updates from industry bellwethers. Hedge fund Armistice Capital has been adding to small- and mid-cap device names, while BlackRock and State Street continue to channel sizable client assets into the space through sector funds and broad index vehicles that leave them among the largest shareholders of blue-chip manufacturers. Recent quarterly results from device leaders have reinforced ...